Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai’s Gene Mutation Analysis Program Now Available in Japan
Chugai Pharmaceutical rolled out its cancer gene panel test kit, FoundationOne CDx Cancer Genomic Profile, on June 3. Based on a partnership deal with Miraca Holdings, its lab testing subsidiary SRL started providing testing services for the program on the…
To read the full story
Related Article
- Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
December 16, 2019
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Genomic Profiling Tests Need More of Private Insurer Involvement: Prof.
July 5, 2019
- Japan Approves Health Coverage for Cancer Gene Panel Tests
May 30, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
BUSINESS
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…